<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitroglycerin (glyceryl trinitrate): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitroglycerin (glyceryl trinitrate): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nitroglycerin (glyceryl trinitrate): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9706" href="/d/html/9706.html" rel="external">see "Nitroglycerin (glyceryl trinitrate): Drug information"</a> and <a class="drug drug_patient" data-topicid="10913" href="/d/html/10913.html" rel="external">see "Nitroglycerin (glyceryl trinitrate): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F202098"><span class="drugH1">Brand Names: US</span>
<ul>
<li>GoNitro [DSC];</li>
<li>Minitran [DSC];</li>
<li>Nitro-Bid;</li>
<li>Nitro-Dur;</li>
<li>Nitro-Time;</li>
<li>Nitrolingual;</li>
<li>NitroMist [DSC];</li>
<li>Nitrostat;</li>
<li>Rectiv</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867705"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Nitroglycerin [DSC];</li>
<li>Minitran [DSC];</li>
<li>MYLAN-Nitro;</li>
<li>Nitro-Dur;</li>
<li>Nitroject;</li>
<li>Nitrolingual;</li>
<li>RHO-Nitro;</li>
<li>Transderm-Nitro [DSC];</li>
<li>Trinipatch 0.2;</li>
<li>Trinipatch 0.4;</li>
<li>Trinipatch 0.6</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054421"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianginal Agent</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Nitrate</span>;</li>
<li>
<span class="list-set-name">Vasodilator</span>;</li>
<li>
<span class="list-set-name">Vasodilator, Coronary</span></li></ul></div>
<div class="block don drugH1Div" id="F53462522"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ce34073-354b-41af-9109-dce5d2fb370e">Vasodilation; perioperative and postoperative, congenital heart defect repair</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasodilation; perioperative and postoperative, congenital heart defect repair</b>
<b>:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Continuous IV infusion: Initial: 0.5 to 1 mcg/kg/minute; titrate by 0.5 to 1 mcg/kg/minute every 20 minutes as needed; maximum dose: 8 to 10 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-32915293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-32915293'])">Ref</a></span>). In one clinical study of 16 pediatric patients &lt;24 months of age (median: 4.4 months; range: 3 days to 23.7 months), a median dose of 1.8 mcg/kg/minute (range: 0.5 to 4 mcg/kg/minute) was reported during and following cardiac surgery with bypass in combination with nitroprusside (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7880995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7880995'])">Ref</a></span>); another trial describes a fixed dose of 1 mcg/kg/minute administered to 15 neonates (mean age: 8 Â± 6 days) after cardiac surgery in conjunction with dopamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10230954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10230954'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="43a68eef-2efe-4a2f-9481-71ab290f121c">Extravasation, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation (sympathomimetic vasopressors), treatment (alternative to phentolamine):</b> Very limited data available; optimal dosing has not been established:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Topical: 2% ointment: 4 <b>mm</b>/kg applied as a thin ribbon to the affected areas; after 8 hours if no improvement, the dose may be repeated at the site; dosing based on a case series in 2 premature neonates (GA: 24 to 31 weeks; at time of treatment: weight: 670 to 1,565 g; PNA: 4 to 40 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1447671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1447671'])">Ref</a></span>). A case report in a premature neonate (GA: 34 weeks; weight: 1,800 g) describes a higher dose of a 1-inch strip (total dose) applied to the affected sites (ankle and wrist) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2510208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2510208'])">Ref</a></span>); however, this is greater than the usual initial adult dose (<sup>1</sup>/<sub>2</sub> inch) for angina; hypotension may occur; carefully monitor blood pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>). <b>Note:</b> Minimal data available from clinical trials/case reports; however, use is described in neonatal extravasation treatment protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23497004','lexi-content-ref-16514862','lexi-content-ref-18069429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23497004','lexi-content-ref-16514862','lexi-content-ref-18069429'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F20614012"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85e174fd-ae50-4d0f-888b-db05d40c02b6">Heart failure; cardiogenic shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure; cardiogenic shock:</b> Limited data available: <b>Note:</b> Continuous IV infusion dosing units vary by age (mcg/kg/minute or <b>mcg/minute</b>); extra precautions should be taken. In adults, tolerance to the hemodynamic and antianginal effects can develop within 24 hours of continuous use; nitrate-free interval (10 to 12 hours/day) is recommended to avoid tolerance development; gradually decrease dose in patients receiving nitroglycerin for prolonged periods to avoid withdrawal reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Continuous IV infusion: Initial: 0.25 to 0.5 mcg/kg/minute; titrate by 1 mcg/kg/minute every 15 to 20 minutes as needed; faster titration may be necessary in some patients; in adults, titration every 3 to 5 minutes has been suggested. Usual dose range: 1 to 5 mcg/kg/minute; usual maximum dose: 10 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AHA.1','lexi-content-ref-3031972','lexi-content-ref-3928187','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AHA.1','lexi-content-ref-3031972','lexi-content-ref-3928187','lexi-content-ref-Park.1'])">Ref</a></span>); doses up to 20 mcg/kg/minute may be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3923176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3923176'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Continuous IV infusion: Initial: 5 to 10 <b>mcg/minute</b>; titrate to a maximum dose of 200 <b>mcg/minute</b>. <b>Note:</b> In adults, doses are titrated every 3 to 5 minutes as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AHA.1','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AHA.1','lexi-content-ref-Park.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="43a68eef-2efe-4a2f-9481-71ab290f121c">Extravasation, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation (sympathomimetic vasopressors), treatment (alternative to phentolamine):</b> Very limited data available; dosing based on experience in neonatal patients; optimal dosing has not been established:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Topical: 2% ointment: 4 <b>mm</b>/kg applied as a thin ribbon to the affected areas; after 8 hours if no improvement, the dose may be repeated at the affected site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1447671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1447671'])">Ref</a></span>). The maximum reported dose is application of a 1-inch strip to the affected site in a neonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2510208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2510208'])">Ref</a></span>); however, this is greater than the usual initial adult dose (<sup>1</sup>/<sub>2</sub> inch) for angina; hypotension may occur; carefully monitor blood pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>). <b>Note:</b> Minimal data available from clinical trials/case reports; however, use has been described in reviews of extravasation treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913','lexi-content-ref-22798353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913','lexi-content-ref-22798353'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51131227"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51131228"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F202103"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9706" href="/d/html/9706.html" rel="external">see "Nitroglycerin (glyceryl trinitrate): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> If a patient who has taken a phosphodiesterase-5 inhibitor for erectile dysfunction develops chest pain, delay nitrate therapy for â¥12 hours after taking avanafil, â¥24 hours after taking sildenafil or vardenafil, and â¥48 hours after taking tadalafil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khera.1','lexi-content-ref-Stendra.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khera.1','lexi-content-ref-Stendra.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="544fdb8d-9360-4b5b-be1d-3c8dd40a45be">Acute decompensated heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute decompensated heart failure (adjunctive agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May consider in patients with volume overload in the absence of symptomatic hypotension to help relieve congestion and dyspnea as an adjunct to IV diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion: IV:</b> Initial: 5 to 10 mcg/minute; titrate as needed based on response and tolerability in increments of 5 to 10 mcg/minute every 3 to 5 minutes up to 200 mcg/minute. Lower doses produce venous dilation; however, arterial vasodilation may occur at high doses. Tachyphylaxis develops within 24 to 48 hours of continuous administration; transition to long-term oral heart failure therapies as soon as possible for ongoing hemodynamic control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21164062','lexi-content-ref-18158484','lexi-content-ref-17447137','lexi-content-ref-26370690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21164062','lexi-content-ref-18158484','lexi-content-ref-17447137','lexi-content-ref-26370690'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cdfe901d-a336-46c4-870c-2fa07ecd9f47">Anal fissure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anal fissure (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer topically as a local vasodilator in conjunction with supportive measures. A 0.2% ointment is not commercially available and must be prepared by a licensed compounding facility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bleday.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bleday.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peri-anal</b>
<b>0.2% or 0.4% ointment:</b> After cleansing, apply around fissure(s) twice daily as directed for 4 weeks; if symptoms persist, continue treatment for another 4 weeks for a total duration of 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9221864','lexi-content-ref-Bleday.2020','lexi-content-ref-10458121','lexi-content-ref-8988115','lexi-content-ref-11008725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9221864','lexi-content-ref-Bleday.2020','lexi-content-ref-10458121','lexi-content-ref-8988115','lexi-content-ref-11008725'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Recommended for acute angina. For prevention of recurrent angina, may use in combination with other anti-anginal therapy (eg, a beta-blocker) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute angina: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>If pain is not relieved or worsens 3 to 5 minutes after 1 sublingual or translingual dose, seek immediate emergency medical attention (eg, call 911) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Sublingual powder (0.4 mg/packet):</i></b> Initial: 1 or 2 packets at onset; repeat every 5 minutes if angina persists; may administer up to 3 packets in a 15-minute period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Sublingual tablet:</i></b> Initial: 0.3 or 0.4 mg at onset; repeat every 5 minutes if angina persists; may administer up to 3 tablets in a 15-minute period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304'])">Ref</a></span>). For patients with refractory angina in the emergency department, up to 0.6 mg as a single dose may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reeder.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reeder.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Translingual 0.4 mg/spray:</i></b> Initial: 1 or 2 sprays at onset; repeat every 5 minutes if angina persists; may administer up to 3 sprays in a 15-minute period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Continuous IV infusion:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Consider IV therapy if angina is not relieved with other dosage forms. Avoid in patients with hypotension (eg, systolic BP &lt;90 mm Hg or &gt;30 mm Hg below baseline), marked bradycardia (eg, &lt;50 beats per minute) or tachycardia (eg, &gt;100 beats per minute), and/or suspected right ventricular infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-Reeder.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-Reeder.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 5 to 10 mcg/minute with continuous cardiac monitoring; titrate as needed to relieve angina symptoms in increments of 5 mcg/minute every 5 to 10 minutes up to 20 mcg/minute; if angina persists at a dose of 20 mcg/minute, may increase by 10 to 20 mcg/minute every 3 to 5 minutes to a maximum dose of 400 mcg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-Reeder.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-Reeder.1','lexi-content-ref-manu.1'])">Ref</a></span>). Tachyphylaxis develops within 24 to 48 hours of continuous nitrate administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prevention of angina (adjunctive therapy):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Sublingual powder (0.4 mg/packet):</i></b> Initial: 1 packet 5 to 10 minutes prior to activities that may provoke angina.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Sublingual tablet:</b></i> Initial: 0.3 or 0.4 mg 5 to 10 minutes prior to activities that may provoke angina.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Translingual 0.4 mg/spray:</b></i> Initial: 1 or 2 sprays 5 to 10 minutes prior to activities that may provoke angina.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Topical 2% ointment:</i></b> Initial: Apply Â½ inch upon rising and apply another Â½ inch 6 hours later; if necessary, the dose may be doubled to 1 inch and subsequently doubled again to 2 inches if response is inadequate. Recommended maximum frequency of administration is 2 doses/day. Include a nitrate-free interval of ~10 to 12 hours each day to minimize the risk of tolerance.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Topical patch, transdermal:</b></i> Initial: 0.2 to 0.4 mg/hour; increase dose as needed based on response and tolerability to a maximum of 0.8 mg/hour. Use a patch-on period of 12 to 14 hours/day and patch-off period (nitrate-free interval) of 10 to 12 hours/day to minimize the risk of tolerance.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>ER capsule, oral: </i></b>Initial: 2.5 to 6.5 mg 3 to 4 times daily; increase dose as needed based on response and tolerability to 26 mg 4 times daily. Include a nitrate-free interval of ~10 to 12 hours each day to minimize the risk of tolerance.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bd6f4ee-171d-42e5-8d85-859fba9996ae">Extravasation management, sympathomimetic vasopressors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management, sympathomimetic vasopressors (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Nitroglycerin is an alternative if phentolamine is not available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical 2% ointment:</b> Apply a 1-inch strip to site of ischemia to cover the affected area; may repeat every 8 hours if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aef7e745-623e-45f6-8649-1f51770dcf85">Hypertension, perioperative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, perioperative (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients with chronic hypertension prior to surgery, restart oral therapies as soon as appropriate once hemodynamically stable. Address underlying causes (eg, pain, agitation, withdrawal, hypervolemia) prior to initiating antihypertensive therapy. Generally used for patients with hypervolemia who are not responsive to IV diuretic therapy, particularly if there is known or suspected ischemic heart disease or heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Broussard.1','lexi-content-ref-London.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Broussard.1','lexi-content-ref-London.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> Initial: 5 to 10 mcg/minute; increase based on BP response and tolerability in increments of 5 mcg/minute every 3 to 5 minutes up to 20 mcg/minute; if no response at a dose of 20 mcg/minute, may increase by 10 to 20 mcg/minute every 3 to 5 minutes to a maximum dose of 200 mcg/minute. Lower doses primarily produce venous dilation; however, arterial vasodilation may occur at high doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Broussard.1','lexi-content-ref-London.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Broussard.1','lexi-content-ref-London.1','lexi-content-ref-manu.1'])">Ref</a></span>). Tachyphylaxis develops within 24 to 48 hours of continuous nitrate administration; if vasodilator requirements continue longer than 24 to 48 hours, transition to an alternative IV or oral vasodilator.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a669e060-0890-4fb4-a8f4-02d01c746a9b">Hypertensive emergency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Limitations of use include variable efficacy compared to other agents (eg, inconsistent and transient BP response), possible reflex tachycardia, and possible reduced cardiac output. May be used as adjunctive therapy for patients with acute coronary syndrome or acute pulmonary edema. In general, goal of therapy is to reduce mean arterial pressure by ~10% to 20% over the first hour, then by an additional 5% to 15% over the next 23 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354','lexi-content-ref-Elliott.2','lexi-content-ref-21986463']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354','lexi-content-ref-Elliott.2','lexi-content-ref-21986463'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion: </b>Initial: 5 mcg/minute; increase based on BP response and tolerability in increments of 5 mcg/minute every 3 to 5 minutes up to 20 mcg/minute; if no response at a dose of 20 mcg/minute, may increase by 10 to 20 mcg/minute every 3 to 5 minutes to a maximum dose of 200 mcg/minute. Lower doses produce venous dilation; however, arterial vasodilation may occur at high doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354','lexi-content-ref-Elliott.1','lexi-content-ref-21986463']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354','lexi-content-ref-Elliott.1','lexi-content-ref-21986463'])">Ref</a></span>). Tachyphylaxis develops within 24 to 48 hours of continuous nitrate administration; if vasodilator requirements continue longer than 24 to 48 hours, transition to an alternative IV or oral vasodilator.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33f92735-c570-4ecf-a501-bca240750fe2">Uterine relaxation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uterine relaxation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used for obstetric emergencies (eg, uterine inversion, difficult fetal extraction due to uterine contraction, internal podalic version of a second twin) or to facilitate extraction of a trapped placenta, external cephalic version, or replacement of deeply prolapsed fetal membranes before placement of a cerclage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hofmeyr.1','lexi-content-ref-Macones.1','lexi-content-ref-Weeks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hofmeyr.1','lexi-content-ref-Macones.1','lexi-content-ref-Weeks.1'])">Ref</a></span>). Dosing provided is an example and may vary based on indication.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 50 mcg once; may repeat at 1-minute intervals as needed to sufficiently relax the uterus; maximum total dose: 250 mcg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1566776','lexi-content-ref-1457119','lexi-content-ref-12900527','lexi-content-ref-8610877','lexi-content-ref-Hofmeyr.1','lexi-content-ref-Macones.1','lexi-content-ref-Weeks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1566776','lexi-content-ref-1457119','lexi-content-ref-12900527','lexi-content-ref-8610877','lexi-content-ref-Hofmeyr.1','lexi-content-ref-Macones.1','lexi-content-ref-Weeks.1'])">Ref</a></span>). If urgent uterine relaxation is required (eg, for fetal extraction), may use initial bolus of 100 to 200 mcg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9492718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9492718'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990308"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (&lt;1% excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987628"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F4040394"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (patch, ointment: 50% to 64%; sublingual powder, lingual spray: &gt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (â¤4%), peripheral edema (lingual spray: â¤2%), syncope (â¤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (lingual spray: â¤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (&gt;2% to 6%), paresthesia (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (all sublingual forms: â¤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (â¤2%), pharyngitis (lingual spray: â¤2%), rhinitis (lingual spray: â¤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, orthostatic hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Application site irritation (patch), circulatory shock, contact dermatitis (ointment, patch), drowsiness, exfoliative dermatitis, fixed drug eruption (ointment, patch), hypersensitivity reaction, hypoxemia (transient), lactic acidosis (Smith 2019), methemoglobinemia, nausea, nonimmune anaphylaxis, pallor, palpitations, rebound hypertension, restlessness, skin rash, tachycardia, vertigo, vomiting</p></div>
<div class="block coi drugH1Div" id="F202082"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to nitroglycerin, other nitrates or nitrites, or any component of the formulation (includes adhesives for transdermal product); concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (avanafil, sildenafil, tadalafil, or vardenafil); concurrent use with soluble guanylate cyclase (sGC) stimulators (eg, riociguat); acute circulatory failure or shock; early myocardial infarction (sublingual tablet only; see <b>Note</b> below); increased intracranial pressure; severe anemia.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications for IV product: Constrictive pericarditis; increased intracranial pressure; pericardial tamponade; restrictive cardiomyopathy.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications for IV product (not in manufacturer's US labeling): Hypotension; uncorrected hypovolemia.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications for translingual product (not in manufacturer's US labeling): Closed angle glaucoma; heart failure (aortic or mitral stenosis, constrictive pericarditis, or hypertrophic cardiomyopathy with left ventricular outflow tract obstruction).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications for transdermal patch (not in manufacturer's US labeling): orthostatic hypotension; myocardial insufficiency due to obstruction (eg, presence of aortic or mitral stenosis or of constrictive pericarditis); increased intraocular pressure.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note</b>
<b>:</b> According to the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines of the management of ST-elevation myocardial infarction (STEMI) and the ACC/AHA guidelines for the management of patients with non-ST-elevation acute coronary syndromes (NSTE-ACS), avoid nitrates in the following conditions: Hypotension (SBP &lt;90 mm Hg or &gt;30 mm Hg below baseline), marked bradycardia or tachycardia, and right ventricular infarction (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]). Sublingual nitroglycerin may be used as initial treatment of ongoing chest pain in patients who may have STEMI or NSTE-ACS (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).</p></div>
<div class="block war drugH1Div" id="F202065"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Headache: Dose-related headaches may occur, especially during initial dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Hypotension/bradycardia: Severe hypotension and shock may occur (even with small doses); paradoxical bradycardia and increased angina pectoris may accompany hypotension. Orthostatic hypotension may also occur; ethanol may accentuate this. Use with caution in volume depletion, preexisting hypotension, constrictive pericarditis, aortic or mitral stenosis, and extreme caution with inferior wall myocardial infarction (MI) and suspected right ventricular involvement. According to the American College of Cardiology Foundation/American Heart Association, avoid use in patients with severe hypotension (SBP &lt;90 mm Hg or &gt;30 mm Hg below baseline), marked bradycardia or tachycardia, and right ventricular MI (ACCF/AHA [O'Gara 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Increased intracranial pressure: Nitroglycerin may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury) (Rangel-Castilla 2008). Use is contraindicated in patients with increased intracranial pressure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Avoid use in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (HF) (AHA/ACC [Ommen 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Intra-anal ointment: Use caution when treating rectal anal fissures with nitroglycerin in patients with suspected or known significant cardiovascular disorders (eg, cardiomyopathies, HF, acute MI); intra-anal nitroglycerin administration may decrease systolic BP and decrease arterial vascular resistance.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Long-acting agents: Avoid use of long-acting agents in acute MI or acute HF; cannot easily reverse effects if adverse events develop.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Transdermal patches: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Tolerance: May occur; cross tolerance to other nitro compounds have been reported. Appropriate dosing is needed to minimize tolerance development.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878566"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults, including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F202076"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Translingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NitroMist: 400 mcg/spray (4.1 g [DSC], 8.5 g [DSC]) [contains menthol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitro-Time: 2.5 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitro-Time: 6.5 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitro-Time: 9 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rectiv: 0.4% (30 g) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitro-Bid: 2% (1 g, 30 g, 60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Sublingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoNitro: 400 mcg (1 ea [DSC], 36 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 24 Hour, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minitran: 0.1 mg/hr (30 ea [DSC]); 0.2 mg/hr (30 ea [DSC]); 0.4 mg/hr (30 ea [DSC]); 0.6 mg/hr (30 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitro-Dur: 0.1 mg/hr (1 ea, 30 ea, 100 ea); 0.2 mg/hr (1 ea, 30 ea); 0.3 mg/hr (1 ea, 30 ea, 100 ea); 0.4 mg/hr (1 ea, 30 ea); 0.6 mg/hr (1 ea, 30 ea); 0.8 mg/hr (1 ea, 30 ea, 100 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1 mg/hr (1 ea, 30 ea); 0.2 mg/hr (1 ea, 30 ea); 0.4 mg/hr (1 ea, 30 ea); 0.6 mg/hr (1 ea, 30 ea, 4350 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg (250 mL); 50 mg (250 mL); 100 mg (250 mL); 5 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Translingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitrolingual: 0.4 mg/spray (4.9 g, 12 g) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg/spray (4.9 g, 12 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitrostat: 0.3 mg, 0.4 mg, 0.6 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.3 mg, 0.4 mg, 0.6 mg</p></div>
<div class="block geq drugH1Div" id="F202061"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F202085"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Extended Release</b> (Nitro-Time Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.5 mg (per each): $1.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 mg (per each): $1.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Nitro-Bid Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $1.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Rectiv Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4% (per gram): $25.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, 24-hour</b> (Nitro-Dur Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/hour (per each): $28.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/hour (per each): $30.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/hour (per each): $63.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/hour (per each): $33.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/hour (per each): $36.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.8 mg/hour (per each): $68.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, 24-hour</b> (Nitroglycerin Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/hour (per each): $1.86 - $2.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/hour (per each): $1.90 - $2.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/hour (per each): $2.17 - $2.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/hour (per each): $2.40 - $3.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nitroglycerin in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/mL 5% (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg/mL 5% (per mL): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nitroglycerin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $1.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nitroglycerin Translingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/spray (per gram): $45.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nitrolingual Translingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/spray (per gram): $67.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Nitroglycerin Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg (per each): $0.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg (per each): $1.02 - $1.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg (per each): $0.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Nitrostat Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg (per each): $0.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg (per each): $1.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg (per each): $0.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867706"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 24 Hour, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minitran: 0.2 mg/hr ([DSC]); 0.4 mg/hr ([DSC]); 0.6 mg/hr ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitro-Dur: 0.2 mg/hr (30 ea); 0.4 mg/hr (30 ea); 0.6 mg/hr (30 ea); 0.8 mg/hr (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Transderm-Nitro: 0.2 mg/hr ([DSC]); 0.4 mg/hr ([DSC]); 0.6 mg/hr ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trinipatch 0.2: 0.2 mg/hr (30 ea, 100 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trinipatch 0.4: 0.4 mg/hr (30 ea, 100 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trinipatch 0.6: 0.6 mg/hr (30 ea, 100 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/hr (30 ea); 0.4 mg/hr (30 ea); 0.6 mg/hr (30 ea); 0.8 mg/hr (30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitroject: 5 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (250 mL); 5 mg/mL (10 mL); 400-5 MCG/ML-% (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Translingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitrolingual: 0.4 mg/spray (4.9 g, 14.49 g) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RHO-Nitro: 0.4 mg/spray (1 ea) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg/spray (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52613436"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Continuous IV infusion: Vials (concentrated solution): Not for direct injection; must be diluted prior to administration; premixed solution in glass containers (100 mcg/mL, 200 mcg/mL, 400 mcg/mL) is available. Administer via infusion pump. Adsorption to soft plastic (eg, PVC) occurs; special administration sets intended for nitroglycerin (nonpolyvinyl chloride) must be used; some inline IV filters also adsorb nitroglycerin; use of these filters should be avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical ointment: Wash hands prior to and after use. Application site should be clean, dry, and hair free. Do not rub into skin.</p>
<p style="text-indent:-2em;margin-left:4em;">Extravasation (sympathomimetic vasopressors), treatment: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula; elevate extremity. Apply nitroglycerin ointment as a thin ribbon to site of ischemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913','lexi-content-ref-1447671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913','lexi-content-ref-1447671'])">Ref</a></span>). May also apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F803176"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Prepare in glass bottles or containers not made with PVC. Adsorption occurs to soft plastic (eg, PVC); use administration sets intended for nitroglycerin. Avoid in-line IV filters that adsorb nitroglycerin. Administer via infusion pump.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-anal:</b> Ointment: Using a finger covering (eg, plastic wrap, surgical glove, finger cot), place finger beside 1 inch measuring guide on the box and squeeze ointment the length of the measuring line directly onto covered finger. Insert ointment into the anal canal using the covered finger up to first finger joint (do not insert further than the first finger joint) and apply ointment around the side of the anal canal. If intra-anal application is too painful, may apply the ointment to the outside of the anus. Wash hands following application.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">ER capsule: Swallow whole. Do not chew, break, or crush. Administer with a full glass of water.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Topical ointment and transdermal formulations are available. If safety and efficacy of nitroglycerin can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, selection of ointment, transdermal, or alternative therapy should be considered in high-risk patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual powder: Empty the contents of packet under the tongue, close mouth, and breathe normally. Allow powder to dissolve without swallowing. Do not rinse or spit for 5 minutes after dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual tablet: Do not chew, crush, or swallow sublingual tablet. Place under tongue and allow to dissolve. Alternately, may be placed in the buccal pouch. May take small sip of water prior to placing tablet under the tongue to aid dissolution.</p>
<p style="text-indent:-2em;margin-left:4em;">Translingual spray: Do not shake container. Prior to initial use, the pump must be primed by spraying 5 times (Nitrolingual) or 10 times (Nitromist) into the air. Priming sprays should be directed away from patient and others. Release spray onto or under tongue. Close mouth immediately after administration; do not inhale spray. Do not expectorate or rinse the mouth for 5 to 10 minutes following administration. Content of the container should be checked periodically; when the container is held upright, the end of the pump should be covered by the fluid in the bottle or the remaining sprays will not deliver the intended dose. If pump is unused for 6 weeks, a single priming spray (Nitrolingual) or 2 priming sprays (Nitromist) should be completed. If pump is unused for 3 months, re-prime with up to 5 sprays (Nitrolingual).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Topical ointment: Wash hands prior to and after use. Application site should be clean, dry, and hair free. Use the provided paper applicator to measure the dose. Place paper on a flat surface, printed side down. Squeeze prescribed amount of ointment onto the paper. Place the paper (ointment side down) on the chest or back. Using the paper, spread in a thin layer over a 2.25 Ã 3.5 inch area. Do not rub into skin. Tape applicator into place.</p>
<p style="text-indent:-2em;margin-left:6em;">Extravasation management, sympathomimetic vasopressors (alternative agent) (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula; apply dry warm compresses; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Alternatives to phentolamine:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover the affected areas; may repeat every 8 hours as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Topical patch, transdermal: Application site should be clean, dry, and hair free. Remove patch after 12 to 14 hours. Rotate patch sites. Dispose of any used of unused patches by folding adhesive ends together, replace in pouch or sealed container and discard properly in trash, away from children and pets.</p></div>
<div class="block uicp drugH1Div" id="F14472968"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 100 <b>mcg</b>/mL, 200 <b>mcg</b>/mL, or 400 <b>mcg</b>/mL.</p></div>
<div class="block sts drugH1Div" id="F202093"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">ER capsules: Store at 25Â°C (77Â°F); excursions permitted to 15Â°C to 30Â°C (59Â°F to 86Â°F). Protect from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Premixed (glass container): Store at 25Â°C (77Â°F); brief exposure up to 40Â°C (104Â°F) does not adversely affect the product. Protect from light until time of use. Avoid excessive heat; protect from freezing.</p>
<p style="text-indent:-2em;margin-left:4em;">Vial: Store intact vial at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions permitted to 15Â°C to 30Â°C (59Â°F to 86Â°F). Protect from light until time of use. The manufacturer recommends only diluting in glass containers but does not provide storage condition recommendations (eg, temperature, duration) once diluted. Nitroglycerin diluted in D5W or NS to concentrations of 200 mcg/mL and 400 mcg/mL in glass or polyolefin containers were found to be stable for 28 days at room temperature or under refrigeration (Wagenknecht 1984). Also, refer to institution-specific policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal ointment: Store at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions are permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F). Keep the tube tightly closed. Use within 8 weeks of first opening.</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual powder: Store at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions permitted to 5Â°C to 40Â°C (41Â°F to 104Â°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablets: Store at 20Â°C to 25Â°C (68Â°F to 77Â°F) in original glass container.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal ointment: Store at 20Â°C to 25Â°C (68Â°F to 77Â°F). Close tightly immediately after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch: Store at 15Â°C to 30Â°C (59Â°F to 86Â°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Translingual spray: Store at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions permitted to 15Â°C to 30Â°C (59Â°F to 86Â°F). Do not forcefully open or burn container after use. Do not spray toward flames.</p></div>
<div class="block usep drugH1Div" id="F53568045"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Extended-release capsule, topical ointment (Nitro-Bid), transdermal patch (eg, NitroDur, Minitran): Prevention of angina pectoris due to coronary artery disease (FDA approved in adults); topical ointment has also been used to treat extravasation of sympathomimetic vasopressors.</p>
<p style="text-indent:-2em;margin-left:2em;">IV solution: Treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and beta-blockers; acute decompensated heart failure (especially when associated with acute myocardial infarction); perioperative hypertension; induction of intraoperative hypotension (All indications: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual powder (GoNitro), sublingual tablets (NitroStat), sublingual spray (Nitrolingual, NitroMist): Treatment or prevention of angina pectoris due to coronary artery disease (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal ointment (Rectiv): Treatment of moderate to severe pain associated with chronic anal fissure (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F202157"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nitroglycerin may be confused with nitrofurantoin, nitroprusside</p>
<p style="text-indent:-2em;margin-left:4em;">Nitro-Bid may be confused with Macrobid</p>
<p style="text-indent:-2em;margin-left:4em;">Nitroderm may be confused with NicoDerm</p>
<p style="text-indent:-2em;margin-left:4em;">Nitrol may be confused with Nizoral</p>
<p style="text-indent:-2em;margin-left:4em;">Nitrostat may be confused with Nilstat, nystatin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nitrocor [Italy, Russia, and Venezuela] may be confused with Natrecor brand name for nesiritide [US, Canada, and multiple international markets]; Nutracort brand name for hydrocortisone in the [US and multiple international markets]; Nitro-Dur [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299768"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F4039431"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within âCYP3A4 Inducers [Strong]â are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the âLaunch drug interactions programâ link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alteplase: Nitroglycerin may decrease the serum concentration of Alteplase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apomorphine: Nitroglycerin may enhance the hypotensive effect of Apomorphine.  Management: Patients taking apomorphine should lie down before and after taking sublingual nitroglycerin. Monitor blood pressure for hypotension and orthostatic hypotension when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May diminish the vasodilatory effect of Nitroglycerin. Nitroglycerin may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). Management: Avoid the use of ergot derivatives in patients receiving nitroglycerin for angina (or in any angina patient) if possible. If combined, monitor for decreased effects of nitroglycerin and increased adverse effects of the ergot derivative (eg, ergotism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Nitroglycerin may diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of ischemia and other adverse effects has been associated with this combination in some pooled analyses. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F11313090"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nitroglycerin crosses the placenta (David 2000).</p>
<p style="text-indent:0em;margin-top:2em;">Following a single maternal IV bolus dose of nitroglycerin at the time of incision prior to cesarean delivery, concentrations in the umbilical cord at birth were significantly lower than the maternal plasma (~1 minute after dosing); a wide variation in maternal plasma concentrations was observed (David 2000). Following application of a transdermal patch 0.4 mg/hour to pregnant women 20 to 36 weeks gestation, concentrations of nitroglycerin were low but detectable in the fetal serum ~1 to 4 hours after the patch was applied (fetal/maternal ratio: 0.23) (Bustard 2003).</p>
<p style="text-indent:0em;margin-top:2em;">IV nitroglycerin is recommended for use in pregnant females with preeclampsia when severe hypertension is associated with pulmonary edema (ESC [Regitz-Zagrosek 2018]). Based on its ability to produce smooth muscle relaxation, nitroglycerin may be used in obstetrical procedures when immediate relaxation of the uterus is needed, such as: uterine inversion following delivery (ACOG 183 2017), uterine relaxation during removal of retained placental tissue (ASA 2016), and management of breech delivery (Caponas 2001; Cluver 2015). Additional data may be necessary to further define the role of nitroglycerin for preterm labor (ACOG 171 2016; Duckitt 2014).</p></div>
<div class="block mopp drugH1Div" id="F53568046"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, and ECG (continuously with IV use).</p></div>
<div class="block pha drugH1Div" id="F202064"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nitroglycerin forms free radical nitric oxide. In smooth muscle, nitric oxide activates guanylate cyclase which increases guanosine 3â5â monophosphate (cGMP) leading to dephosphorylation of myosin light chains and smooth muscle relaxation. Produces a vasodilator effect on the peripheral veins and arteries with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload; dilates coronary arteries and improves collateral flow to ischemic regions. For use in rectal fissures, intra-anal administration results in decreased sphincter tone and intra-anal pressure.</p></div>
<div class="block phk drugH1Div" id="F202081"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Sublingual tablet: 1 to 3 minutes; Translingual spray: Similar to sublingual tablet; Extended release: ~60 minutes; Topical: 15 to 30 minutes; Transdermal: ~30 minutes; IV: Immediate</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Sublingual powder: 7 minutes; Sublingual tablet: 5 minutes; Translingual spray: 4 to 15 minutes; Extended release: 2.5 to 4 hours; Topical: ~60 minutes; Transdermal: 120 minutes; IV: Immediate</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Sublingual tablet: At least 25 minutes; Translingual spray: Similar to sublingual tablet; Extended release: 4 to 8 hours (Gibbons 2003); Topical: 7 hours; Transdermal: 10 to 12 hours; IV: 3 to 5 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~3 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 60%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive first-pass effect; metabolized hepatically to glycerol di- and mononitrate metabolites via liver reductase enzyme; subsequent metabolism to glycerol and organic nitrate; nonhepatic metabolism via red blood cells and vascular walls also occurs</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~1 to 4 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as inactive metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F202086"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nitro Dur | Nitroderm | Nitrol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dauxona | Enetege | Enetege-safejet | Minitran | Nitradisc | Nitro Dur | Nitroderm | Nitrogray | Oxycardin | Trinitron</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nitro | Nitro Mack | Nitroderm | Nitrodur | Nitrolingual | Perlinganit | Rectogesic</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Glyceryl trinitrat | Gtn pohl | Lycinate | Minitran | Nitradisc | Nitro bid | Nitro Dur | Nitrostat | Rectogesic | Transiderm-nitro</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Angicard | Nitrin | Nitrocap | Nitrovas | Rectocare | Repane | Trocer</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Diafusor | Minitran | Nitro m bid | Nitroderm | Nitrodyl | Nitrolingual | Nysconitrine | Rectogesic | Trinipatch | Willlong</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Myonit insta</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Nitroderm | Nitroglycerin | Nitronal Aqueous | Perlinganit</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Nitradisc | Nitroderm | Nitronal | Tridil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Deponit 10 | Deponit 5 | Minitran | Minitran 10 | Nitro dur 10 | Nitro Mack | Nitroderm | Nitroglycerin Bioren | Nitroglycerin wander | Nitrolingual | Perlinganit | Rectogesic | Trinitrosan</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">CÃ´te d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Myonit insta</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Angiolingual | Nitrocor | Nitroderm | Nitroglicerina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nitro Mack | Nitroderm | Nitrodisc | Nitroglycerin | Nitroglycerin patches (ii) | Nitrostat | Pai luo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Enetege | Imectin | Nitradisc | Nitroglicerina | Tridil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nitro | Nitroderm | Nitroglycerin | Nitromack | Nitropelet | Perlinganit</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aquo-trinitrosan | Corangin nitrospray | Coro nitro | Deponit | Glyceroltrinitrat carinopharm | Minitrans | Neos nitro opt | Nitradisc | Nitriderm | Nitro | Nitro Dur | Nitro gesanit | Nitro Mack | Nitro solvay infus n | Nitroderm | Nitrolingual | Nitronal | Perlinganit | Rectogesic | Trinitrosan</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Glycerylnitrat "SAD"</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Nitroderm</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Nitroderm | Nitroglicerina | Nitroglicerina sanderson</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Maycor nitrospray | Minitran | Myonit insta | Nitro | Nitro Mack | Nitroderm | Nitroglycerin | Nitroglycerin nycomed | Nitroglytseriin ns | Rectogesic</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cardiocare | Coronolax | Deponit nt | Glycerotone | Nitro Mak Retard | Nitrocare | Nitrocine | Nitroderm | Nitromack | Nitronal | Nitrong | Nitrotard | Tridil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cordiplast | Dermatrans | Diafusor | Epinitril | Minitran | Nitradisc | Nitro Dur | Nitroderm | Nitroderm matrix | Nitrofix | Nitroplast | Rectogesic | Solinitrina | Trinipatch | Vernies</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Deponit nt | Minitran | Nitro | Nitroglycerin Orion | Nitromex | Nitropront | Nitroretard | Perlinganit | Rectogesic | Transiderm-nitro</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cordipatch | Diafusor | Discotrine | Epinitril | Lenitral percutane | Nitriderm | Nitronal | Rectogesic | Trinipatch | Trinitran | Trinitrine | Trinitrine laleuf | Trinitrine mylan | Trinitrine simple laleuf</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Glyceryl trin dc | Glyceryl trin kent | Glyceryl trinitrate cox | Minitran | Minitran old | Nitro Dur | Nitrocine | Nitroglycerine | Nitronal | Percutol | Percutol rorer | Rectogesic | Retrogesic | Transiderm Nitro | Tridil ahs | Trintek</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cardiplast | Carina | Epinitril | Nitro Mack | Nitrocerin | Nitrodyl | Nitrolingual | Nitrong | Nitroretard | Pancoran | Sodemethin | Supranitrin | Trinipatch | Trinitrina</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Angised | Deponit | Glyceryl trinitrat | Nitradisc | Nitro | Nitro bid | Nitro Mack | Nitroderm | Nitroglycerin | Nitroglyn | Nitrolingual</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Gilustenon | Nitradisc | Nitro | Nitro Dur | Nitro Mack | Nitroderm | Nitroglicerina bioindustria | Nitrolingual | Nitromint | Nitromint nt | Perlinganit | Rectogesic</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Carnit | Deponit | Glyceryl trinitrat | Minitran | Nitradisc | Nitro Mack | Nitrocine | Nitroderm | Nitroglycerin | Nitrokaf</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Angised | Deponit | Nitrocine | Nitrodur | Nitronal | Percutol | Rectogesic | Transiderm Nitro</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nitroderm | Nitrovis</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Angiplat | Angispan tr | Angistat | GTN Sorbitrate | Minitran | Myonit insta | Myovin | NG care | Nglong | Nitrocure | Nitroday | Nitroderm | Nitrogesic | Nitroglyn | Nitroject | Nitroplus | Nitrovir | Sorbitrate insta | Top nitro | Vasovin XL</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adesicor | Adesitrin | Deponit | Dermatrans | Epinitril | Keritrina | Minitran | Niglina | Niredil | Nitraket | Nitro Dur | Nitrocor | Nitroderm | Nitroglicerina bioindustria | Nitroglicerina doc generici | Nitroglicerina eg | Nitroglicerina pht | Nitroglicerina provvisoria | Nitroglicerina teva | Nitroglicerina zentiva | Nitrosylon | Perganit | Rectogesic | Top nitro | Triniplas | Trinitrina | Venitrin T</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nitrocine | Nitroderm</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dydrene | Herzer | Meditrans | Millis | Millisrol | Minitro | Myocor | Ngo | Nitroderm | Nitroglycerin | Nitroglycerin acc | Nitroglycerin hk | Nitroglycerin te | Nitropen | Vasolator</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Niredil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Angiderm | Deponit | Hana nitroglycerin | Millisrol | Minitran | Myungmoon nitroglycerin | Nitcerin | Nitro | Nitrobid | Nitroderm | Nitrogesic | Nitroglycerin | Nitrolingual | Nitrostat | Pasarect | Perlinganit | Rectocare | Rectogesic</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Angised | Nitroderm | Tridil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Discotrine | Lenitral | Nitro bid | Nitroderm | Nitromack | Rectogesic</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Deponit nt | Nitro | Nitro pohl | Nitrocine | Nitroderm | Nitroglycerin | Nitroglycerinum lek | Nitrogranulong | Nitromack | Perlinganit | Rectogesic | Trinitrolong</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Diafusor | Minitran | Nitro m bid | Nitroderm | Nitrodyl | Nitrolingual | Nitromack | Nysconitrine | Rectogesic | Trinipatch | Willlong</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Minitran | Nitro | Nitro Dur | Nitrocine | Nitroderm | Nitroglycerin | Nitroglycerin dak | Nitroglycerinum | Nitrogranulong | Nitromack | Perlinganit | Rectogesic | Trinitrolong</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lenitral | Nitroderm | Trinipatch</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Angiopohl | Brudanet | Cardinit | Minitran | Nitradisc | Nitro Dur | Nitroderm | Nitroderm tts</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Angised | Deponit | Glyceryl trinitrat | Myonit insta | Nitrocine | Nitroderm | Nitroglycerin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Minitran | Nitro Dur | Nitrobaat | Nitroglycerin | Nitroglycerine | Nitroglycerine teva | Nitrostat | Nitrozell | Transiderm | Transiderm Nitro | Transiderm-nitro | Trinipatch</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Glyceroltrinitrat carinopharm | Glycerylnitrat | Glycerylnitrat i essex | Minitran | Nitradisc | Nitro Dur | Nitroglycerin | Nitroglycerin abboxia | Nitroglycerin nycomed | Nitroglycerin orifarm | Nitromex | Nitroven | Rectogesic | Suscard | Transiderm-nitro</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Glyceryl trinitrat | Minitran | Nitroderm | Nitroglycerin | Nitronal | Nitronal Aqueous | Rectogesic</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nitroglicerina | Nitropack d-r</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Minitran | Nitronal Aqueous | Nitrosan | Nitrostat | Perlinganit | Transderm Nitro</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Angilingual | Anginor | Angiocard | Angiocard sr | Angised | Deponit | Niglys | Nitromack | Nitronal | Nitroscot</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Lenitral | Nirmin | Nitracor | Nitro bid | Nitrocard | Nitroderm | Nitrodisk | Nitroglycerin | Nitroglycerinum | Nitromack | Perlinganit | Polnitrin | Rectogesic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Gonitro | Minitran | Nitrek | Nitro bid | Nitro Dur | Nitro Time | Nitrodil | Nitrodisc | Nitroglycerin | Nitroglyn | Nitrol | Nitronal | Nitroquick | Nitrostat | Nitrotab | Rectiv | Transderm Nitro | Tridil</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Epinitril | Glyceryl trinitrat | Gtn | Nitradisc | Nitro Dur | Nitroderm | Nitroglicerina | Nitroglicerina Abbott | Nitroglicerina mylan | Plastranit | Rectogesic | Trinipatch</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dauxona | Nitroglicerina sanderson</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Glytrin Spray | Myonit Insta | Nitrocin | Nitrocine | Nitroderm TTS 10 | Nitroderm TTS 15 | Nitroderm TTS 5</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Nitroretard</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nirmin | Nitro | Nitro Mack | Nitro Pohl Infuse | Nitro Time | Nitrocardin | Nitrocor | Nitroderm | Nitroglycerin | Nitromack | Nitropercuten | Nitrospray | Perlinganit | Trinitrolong</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Glyceryl trinitrat | Nitro Dur | Nitro Mack | Nitroderm | Tridil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Minitran | Nitroglycerin | Nitroglycerin abboxia | Nitroglycerin biophausia | Nitroglycerin dak | Nitroglycerin Ebb | Nitroglycerin Recip | Nitroretard | Rectogesic | Transiderm-nitro</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Angised | Deponit | Minitran | Nitrocine | Nitroderm</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Minitran | Nitro Dur | Nitroderm | Nitrofix | Nitroglicerina sandoz | Nitronal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Nitroderm | Nitromack | Nitropelet | Perlinganit</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Glyceryl trinitrate dbl | Minitran | Nitradisc | Nitro Mack | Nitrocine | Nitroderm | Nitroglycerin | Nitroject | Vasonit | Willong</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Diafusor</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anrecta | Deponit | Glisenit | Glyceryl trinitrat | Nitradisc | Nitroderm | Perlinganit | Rectoderm | Rectogesic | Trinity</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Glyceryl trinitrat | Goyceryl trinitrat | Millisrol | Minitran | Nitro Mack | Nitroderm | Nitrodisc | Nitroglycerin | Nitrol | Nitrolingual | Nitrostat | Tridil</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Nitro | Nitro Mack | Nitro mick | Nitro Time | Nitroglycerin | Nitromack | Nitromax | Perlinganit | Trinitrolong</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dauxona | Enetege | Minitran | Niglinar | Nitroderm | Nitrodur | Nitroglicerina | Nitroglycerin | Nitroprontan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Deponit | Minitran | Nitrocor | Nitroderm | Nitroglicerina | Nitromack</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Nicerol | Nitralmyl</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Nitrocine | Tridil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-1566776">
<a name="1566776"></a>Altabef KM, Spencer JT, Zinberg S. Intravenous nitroglycerin for uterine relaxation of an inverted uterus. <i>Am J Obstet Gynecol</i>. 1992;166(4):1237-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/1566776/pubmed" id="1566776" target="_blank">1566776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27661654">
<a name="27661654"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice BulletinsâObstetrics. ACOG Practice Bulletin No. 171: Management of preterm labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi:10.1097/AOG.0000000000001711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/27661654/pubmed" id="27661654" target="_blank">27661654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.2017">
<a name="ACOG.2017"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice BulletinsâObstetrics. ACOG Practice Bulletin No. 183: Postpartum hemorrhage. <i>Obstet Gynecol</i>. 2017;130(4):e168-e186. doi:10.1097/AOG.0000000000002351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/28937571/pubmed" id="28937571" target="_blank">28937571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AHA.1">
<a name="AHA.1"></a>American Heart Association. Nitroglycerin. In: AHA 2016 PALS Digital Pocket Reference Card. Published 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26580836">
<a name="26580836"></a>American Society of Anesthesiologists Task Force on Obstetric Anesthesia; Society for Obstetric Anesthesia and Perinatology. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists (ASA) Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. <i>Anesthesiology</i>. 2016;124(2):270-300. doi:10.1097/ALN.0000000000000935<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/26580836/pubmed" id="26580836" target="_blank">26580836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed February 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3031972">
<a name="3031972"></a>Artman M, Graham TP Jr. Guidelines for vasodilator therapy of congestive heart failure in infants and children.<i> Am Heart J</i>. 1987;113(4):994-1005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/3031972/pubmed" id="3031972" target="_blank">3031972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9492718">
<a name="9492718"></a>Axemo P, Fu X, Lindberg B, Ulmsten U, WessÃ©n A. Intravenous nitroglycerin for rapid uterine relaxation. <i>Acta Obstet Gynecol Scand</i>. 1998;77(1):50-53. doi:10.1034/j.1600-0412.1998.770111.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9492718/pubmed" id="9492718" target="_blank">9492718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9221864">
<a name="9221864"></a>Bacher H, Mischinger HJ, Werkgartner G, et al. Local nitroglycerin for treatment of anal fissures: an alternative to lateral sphincterotomy? <i>Dis Colon Rectum</i>. 1997;40(7):840-845. doi:10.1007/BF02055444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9221864/pubmed" id="9221864" target="_blank">9221864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1457119">
<a name="1457119"></a>Bayhi DA, Sherwood CD, Campbell CE. Intravenous nitroglycerin for uterine inversion. <i>J Clin Anesth</i>. 1992;4(6):487-488. doi:10.1016/0952-8180(92)90225-p<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/1457119/pubmed" id="1457119" target="_blank">1457119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bleday.2020">
<a name="Bleday.2020"></a>Bleday R. Anal fissure: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20645601">
<a name="20645601"></a>BÃ¶ttiger Y. Lack of Data on Glyceryl Trinitrate Risks in Breast Feeding. <i>Lakartidningen</i>. 2010;107(22):1483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/20645601/pubmed" id="20645601" target="_blank">20645601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Broussard.1">
<a name="Broussard.1"></a>Broussard D, Ural K. Cardiovascular problems in the post-anesthesia care unit (PACU). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14710114">
<a name="14710114"></a>Bustard MA, Ryan G, Seaward G, et al. Human Maternal and Fetal Plasma Glyceryl Trinitrate Concentrations. <i>Am J Obstet Gynecol</i>. 2003;189(6):1777-1778.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/14710114/pubmed" id="14710114" target="_blank">14710114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11314836">
<a name="11314836"></a>Caponas G. Glyceryl trinitrate and acute uterine relaxation: a literature review. <i>Anaesth Intensive Care</i>. 2001;29(2):163-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/11314836/pubmed" id="11314836" target="_blank">11314836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12900527">
<a name="12900527"></a>Chedraui PA, Insuasti DF. Intravenous nitroglycerin in the management of retained placenta. <i>Gynecol Obstet Invest</i>. 2003;56(2):61-64. doi:10.1159/000072734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/12900527/pubmed" id="12900527" target="_blank">12900527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25674710">
<a name="25674710"></a>Cluver C, Gyte GM, Sinclair M, Dowswell T, Hofmeyr GJ. Interventions for helping to turn term breech babies to head first presentation when using external cephalic version. <i>Cochrane Database Syst Rev</i>. 2015;(2):CD000184. doi:10.1002/14651858.CD000184.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/25674710/pubmed" id="25674710" target="_blank">25674710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21164062">
<a name="21164062"></a>Coons JC, McGraw M, Murali S. Pharmacotherapy for acute heart failure syndromes. <i>Am J Health Syst Pharm</i>. 2011;68(1):21-35. doi:10.2146/ajhp100202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/21164062/pubmed" id="21164062" target="_blank">21164062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10764480">
<a name="10764480"></a>David M, Walka MM, Schmid B, et al. Nitroglycerin Application During Cesarean Delivery: Plasma Levels, Fetal/Maternal Ratio of Nitroglycerin, and Effects in Newborns.<i> Am J Obstet Gynecol</i>. 2000;182(4):955-961.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/10764480/pubmed" id="10764480" target="_blank">10764480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8610877">
<a name="8610877"></a>Dayan SS, Schwalbe SS. The use of small-dose intravenous nitroglycerin in a case of uterine inversion. <i>Anesth Analg</i>. 1996;82(5):1091-1093. doi:10.1097/00000539-199605000-00041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/8610877/pubmed" id="8610877" target="_blank">8610877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2510208">
<a name="2510208"></a>Denkler KA, Cohen BE. Reversal of Dopamine Extravasation Injury With Topical Nitroglycerin Ointment. <i>Plast Reconstr Surg</i>. 1989;84(5):811-813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/2510208/pubmed" id="2510208" target="_blank">2510208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24809331">
<a name="24809331"></a>Duckitt K, Thornton S, O'Donovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. <i>Cochrane Database Syst Rev</i>. 2014;(5):CD002860. doi:10.1002/14651858.CD002860.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/24809331/pubmed" id="24809331" target="_blank">24809331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9451516">
<a name="9451516"></a>Dufour P, Vinatier D, Puech F. The use of intravenous nitroglycerin for cervico-uterine relaxation: a review of the literature. <i>Arch Gynecol Obstet</i>. 1997;261(1):1-7. doi:10.1007/s004040050189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9451516/pubmed" id="9451516" target="_blank">9451516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18158484">
<a name="18158484"></a>Elkayam U, Janmohamed M, Habib M, Hatamizadeh P. Vasodilators in the management of acute heart failure. <i>Crit Care Med</i>. 2008;36(1)(suppl):S95-S105. doi:10.1097/01.CCM.0000297161.41559.93<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/18158484/pubmed" id="18158484" target="_blank">18158484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliott.1">
<a name="Elliott.1"></a>Elliott WJ, Varon J. Drugs used for the treatment of hypertensive emergencies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliott.2">
<a name="Elliott.2"></a>Elliott WJ, Varon J. Evaluation and treatment of hypertensive emergencies in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3923176">
<a name="3923176"></a>Friedman WF, George BL. Treatment of Congestive Heart Failure by Altering Loading Conditions of the Heart. <i>J Pediatr</i>. 1985;106(5):697-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/3923176/pubmed" id="3923176" target="_blank">3923176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12570960">
<a name="12570960"></a>Gibbons RJ, Abrams J, Chatterjee K, et al; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). <i>J Am Coll Cardiol</i>. 2003;41(1):159-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/12570960/pubmed" id="12570960" target="_blank">12570960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GoNitro.1">
<a name="GoNitro.1"></a>GoNitro (nitroglycerin) [prescribing information]. Canton, MS: Allegis Pharmaceuticals LLC; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hofmeyr.1">
<a name="Hofmeyr.1"></a>Hofmeyr GJ. Delivery of the singleton fetus in breech presentation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17447137">
<a name="17447137"></a>Hollenberg SM. Vasodilators in acute heart failure. <i>Heart Fail Rev</i>. 2007;12(2):143-147. doi:10.1007/s10741-007-9017-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/17447137/pubmed" id="17447137" target="_blank">17447137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs.</i> 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928187">
<a name="3928187"></a>Ilbawi MN, Idriss FS, DeLeon SY, Berry TE, Duffy CE, Paul MH. Hemodynamic effects of intravenous nitroglycerin in pediatric patients after heart surgery. <i>Circulation</i>. 1985;72(3, pt 2):II101-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/3928187/pubmed" id="3928187" target="_blank">3928187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10458121">
<a name="10458121"></a>Kennedy ML, Sowter S, Nguyen H, Lubowski DZ. Glyceryl trinitrate ointment for the treatment of chronic anal fissure: results of a placebo-controlled trial and long-term follow-up. <i>Dis Colon Rectum</i>. 1999;42(8):1000-1006. doi:10.1007/BF02236691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/10458121/pubmed" id="10458121" target="_blank">10458121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khera.1">
<a name="Khera.1"></a>Khera M. Treatment of male sexual dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10230954">
<a name="10230954"></a>Laitinen P, Happonen JM, Sairanen H, et al. Amrinone Versus Dopamine and Nitroglycerin in Neonates After Arterial Switch Operation for Transposition of the Great Arteries. <i>J Cardiothorac Vasc Anesth</i>. 1999;13(2):186-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/10230954/pubmed" id="10230954" target="_blank">10230954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9262751">
<a name="9262751"></a>Lee HA, Anderson PO. Giving Partial Doses of Transdermal Patches. <i>Am J Health Syst Pharm</i>. 1997;54(15):1759-1760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9262751/pubmed" id="9262751" target="_blank">9262751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-London.1">
<a name="London.1"></a>London MJ. Hemodynamic management during anesthesia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9075542">
<a name="9075542"></a>Lowenwirt IP, Zauk RM, Handwerker SM. Safety of intravenous glyceryl trinitrate in management of retained placenta. <i>Aust N Z J Obstet Gynaecol</i>. 1997;37(1):20-24. doi:10.1111/j.1479-828x.1997.tb02212.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9075542/pubmed" id="9075542" target="_blank">9075542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8988115">
<a name="8988115"></a>Lund JN, Scholefield JH. A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. <i>Lancet</i>. 1997;349(9044):11-14. doi:10.1016/S0140-6736(96)06090-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/8988115/pubmed" id="8988115" target="_blank">8988115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Macones.1">
<a name="Macones.1"></a>Macones G. Puerperal uterine inversion. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21986463">
<a name="21986463"></a>Marik PE, Rivera R. Hypertensive emergencies: an update. <i>Curr Opin Crit Care</i>. 2011;17(6):569-580. doi:10.1097/MCC.0b013e32834cd31d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/21986463/pubmed" id="21986463" target="_blank">21986463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26370690">
<a name="26370690"></a>Mebazaa A, Tolppanen H, Mueller C, et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. <i>Intensive Care Med.</i> 2016;42(2):147-163. doi:10.1007/s00134-015-4041-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/26370690/pubmed" id="26370690" target="_blank">26370690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minitran.1">
<a name="Minitran.1"></a>Minitran (nitroglycerin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitro-Bid.1">
<a name="Nitro-Bid.1"></a>Nitro-Bid (nitroglycerin) [prescribing information]. Melville, NY: Savage Pharmaceuticals; September 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitro-Dur.1">
<a name="Nitro-Dur.1"></a>Nitro-Dur (nitroglycerin) [prescribing information]. Orlando, FL: Ingenus Pharmaceuticals LLC; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitro-Dur.2">
<a name="Nitro-Dur.2"></a>Nitro-Dur (nitroglycerin) [product monograph]. Mississauga, Ontario, Canada: Dr. Reddy's Laboratories Canada Inc; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitro-Time.1">
<a name="Nitro-Time.1"></a>Nitro-Time (nitroglycerin) [prescribing information]. Farmingdale, NY: Time Cap Labs; October 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Nitroglycerin in 5% dextrose injection (nitroglycerin) [prescribing information]. Deerfield, IL: Baxter; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanRegent.1">
<a name="AmericanRegent.1"></a>Nitroglycerin injection [prescribing information]. Shirley, NY: American Regent Inc; November 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitroject.1">
<a name="Nitroject.1"></a>Nitroject (nitroglycerin) [product monograph]. Montreal, Canada: Omega Laboratories Ltd; June 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitrolingual.1">
<a name="Nitrolingual.1"></a>Nitrolingual (nitroglycerin) [prescribing information]. Jacksonville, FL: Espero Pharmaceuticals Inc; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitrolingual.2">
<a name="Nitrolingual.2"></a>Nitrolingual Pumpspray (nitroglycerin) [prescribing information]. Canton, MS: Allegis Pharmaceuticals LLC; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitrolingual.3">
<a name="Nitrolingual.3"></a>Nitrolingual Pumpspray (nitroglycerin) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NitroMist.1">
<a name="NitroMist.1"></a>NitroMist (nitroglycerin) [prescribing information]. Scottsdale, AZ: Evus Pharmaceuticals LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitrostat.1">
<a name="Nitrostat.1"></a>Nitrostat (nitroglycerin) [prescribing information]. New York, NY: Parke-Davis; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21946463">
<a name="21946463"></a>O'Sullivan S, Keith MP. Raynaud phenomenon of the Nipple: A Rare Finding in Rheumatology Clinic. <i>J Clin Rheumatol</i>. 2011;17(7):371-372.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/21946463/pubmed" id="21946463" target="_blank">21946463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park MK, Salamat M. Appendix E: Drugs used in pediatric cardiology. In: <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021: 477-492.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18514825">
<a name="18514825"></a>Rangel-Castilla L, Gopinath S, Robertson CS. Management of intracranial hypertension. <i>Neurol Clin</i>. 2008;26(2):521-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/18514825/pubmed" id="18514825" target="_blank">18514825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rectiv.1">
<a name="Rectiv.1"></a>Rectiv (nitroglycerin) [prescribing information]. Birmingham, AL: Aptalis Pharma US Inc; January 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rectiv.2">
<a name="Rectiv.2"></a>Rectiv (nitroglycerin) intra-anal ointment 0.4% [prescribing information]. Irvine, CA: Allergan USA Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reeder.1">
<a name="Reeder.1"></a>Reeder GS. Nitrates in the management of acute coronary syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23497004">
<a name="23497004"></a>Restieaux M, Maw A, Broadbent R, Jackson P, Barker D, Wheeler B. Neonatal extravasation injury: prevention and management in Australia and New Zealand - a survey of current practice. <i>BMC Pediatr</i>. 2013;13:34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/23497004/pubmed" id="23497004" target="_blank">23497004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RHO-Nitro.1">
<a name="RHO-Nitro.1"></a>RHO-Nitro Pumpspray (nitroglycerin sublingual spray) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16514862">
<a name="16514862"></a>Sawatzky-Dickson D, Bodnaryk K. Neonatal intravenous extravasation injuries: evaluation of a wound care protocol. <i>Neonatal Netw</i>. 2006;25(1):13-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/16514862/pubmed" id="16514862" target="_blank">16514862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31361914">
<a name="31361914"></a>Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. <i>Pharmacotherapy</i>. 2019;39(9):946-963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/31361914/pubmed" id="31361914" target="_blank">31361914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy.</i> 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stendra.1">
<a name="Stendra.1"></a>Stendra (avanafil) [prescribing information]. Chesterbrook, PA: Auxilium; April 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taylor.1">
<a name="Taylor.1"></a>Taylor T, Kennedy D. Safety of topical glyceryl trinitrate in the treatment of anal fissure in breastfeeding women. <i>Birth Defects Res A Clin Mol Teratol</i>. 2008;82:411.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18069429">
<a name="18069429"></a>Thigpen JL. Peripheral intravenous extravasation: nursing procedure for initial treatment. <i>Neonatal Netw</i>. 2007;26(6):379-384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/18069429/pubmed" id="18069429" target="_blank">18069429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32915293">
<a name="32915293"></a>Tobias JD, Naguib A, Simsic J, Krawczeski CD. Pharmacologic control of blood pressure in infants and children. <i>Pediatr Cardiol</i>. 2020;41(7):1301-1318. doi:10.1007/s00246-020-02448-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/32915293/pubmed" id="32915293" target="_blank">32915293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22798353">
<a name="22798353"></a>Treadwell T. The management of intravenous infiltration injuries in infants and children. <i>Ostomy Wound Manage</i>. 2012;58(7):40-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/22798353/pubmed" id="22798353" target="_blank">22798353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6437221">
<a name="6437221"></a>Wagenknecht DM, Baaske DM, Alam AS, Carter JE, Shah J. Stability of nitroglycerin solutions in polyolefin and glass containers. <i>Am J Hosp Pharm</i>. 1984;41(9):1807-1811.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/6437221/pubmed" id="6437221" target="_blank">6437221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weeks.1">
<a name="Weeks.1"></a>Weeks A. Retained placenta after vaginal birth. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133354">
<a name="29133354"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/29133354/pubmed" id="29133354" target="_blank">29133354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7880995">
<a name="7880995"></a>Williams RS, Mickell JJ, Young ES, et al. Methemoglobin Levels During Prolonged Combined Nitroglycerin and Sodium Nitroprusside Infusions in Infants After Cardiac Surgery. <i>J Cardiothorac Vasc Anesth</i>. 1994;8(6):658-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/7880995/pubmed" id="7880995" target="_blank">7880995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1447671">
<a name="1447671"></a>Wong AF, McCulloch LM, Sola A. Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates. <i>J Pediatr</i>. 1992;121(6):980-983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/1447671/pubmed" id="1447671" target="_blank">1447671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11008725">
<a name="11008725"></a>Zuberi BF, Rajput MR, Abro H, Shaikh SA. A randomized trial of glyceryl trinitrate ointment and nitroglycerin patch in healing of anal fissures. <i>Int J Colorectal Dis</i>. 2000;15(4):243-245. doi:10.1007/s003840000230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/11008725/pubmed" id="11008725" target="_blank">11008725</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12646 Version 512.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
